In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Towner
OMRF discovers compound that could fight deadly cancer
Glioblastoma is an aggressive form of brain cancer with no cure, but a new OMRF discovery offers hope.
Oblato acquires all rights to glioblastoma drug from OMRF
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Staying alive: Can an experimental OMRF drug stop Mike Schuster’s brain cancer?
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
OMRF hosts 2018 Loyal Donors reception
OMRF officials brought more than 110 long-time donors together from across the state to celebrate their dedicated supporters at the annual Loyal Donor Society reception.
Q BioMed Inc. finalizes license agreement with OMRF, RGCB
QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.